NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • Getting involved with research
    • Researcher Guidance
    • Post an opportunity for patient and public involvement
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > COVID-19 > Study investigates responses to COVID-19 treatment in chronic lymphoid leukaemia patients

Study investigates responses to COVID-19 treatment in chronic lymphoid leukaemia patients

27 August 2021 · Listed under COVID-19, Haematology and Stem Cells, Oxford Blood Group

The COVID-19 pandemic has led to understandable anxiety within the blood cancer community about how their illness may affect their ability to overcome COVID-19 infection.

Members of the Oxford Centre for Haematology have led a collaborative research project looking at the response of patients with chronic lymphocytic leukaemia (CLL) who were infected with COVID-19.

The results of the study, which was supported by the NIHR oxford BRC, have been reported in the journal Blood. 

CLL is a type of blood cancer where white blood cells called B lymphocytes grow out of control. The disease is typically slow to develop, showing few symptoms at the beginning. Around 4,000 people are diagnosed with CLL each year in the UK, more commonly among people over 60 years old, and there are a variety of treatments available, depending on the stage of disease progression.  

In the recent study, investigators from 45 centres selected 374 patients with CLL who were diagnosed with COVID-19 in two time periods: February-April 2020; and May 2020-January 2021.

Trends showed that CLL patients diagnosed with COVID-19 in spring 2020 experienced a high case fatality rate (31-33%). At this point the, the US authorities permitted the use of dexamethasone for COVID-19-infected patients requiring oxygen and a wider set of treatment guidelines were disseminated.

There followed an improvement in survival for patients infected with COVID-19 after May 2020, which was likely due to improvements in treatment. This trend in overall survival for CLL patients mirrored that observed in the general population.

Further analysis compared the effect of a range of treatments including dexamethasone, remdesivir, convalescent plasma, corticosteroids and hydroxychloroquine in the CLL COVID-19 patient group.

Researchers also analysed how long patients required intensive care treatment in hospital, how many needed oxygen, whether their BTKi cancer therapy was continued during COVID infection, and whether there was any correlation of the overall survival rate to age, gender or cumulative illness rating scale. 

A final question concerned the efficacy of COVID-19 vaccines to promote an immune response in CLL patients. Serology tests showed that 60% of CLL patients developed COVID-19 antibodies, although the response varied considerably. Ongoing research aims to understand the immune response to COVID-19 vaccination. 

“Since the beginning of the COVID-19 pandemic, medical staff have worked very hard to optimise treatment for patients, and it is gratifying to see the improvements in survival of CLL patients to COVID-19 infection” said Dr Toby Eyre, Consultant Haematologist at the Oxford University Hospitals NHS Foundation Trust, and the co-lead of the research project.

“The Oxford Centre for Haematology, with funding from the NIHR Oxford BRC, is in a strong position to coordinate both retrospective and clinical trials to add to the body of knowledge about how best to treat blood cancer patients during the COVID pandemic.”

Read the research paper. 

Find out more about the Oxford Centre for Haematology.

← New study launched to understand vaccine escape
Researchers develop algorithm to diagnose deep vein thrombosis →

News

  • BRC study outlines researchers training needs and barriers 20 May 2022
  • Three new Blood and Transplant Research Units created in Oxford 18 May 2022
  • Oxford’s medical, health and life sciences research excellence recognised 12 May 2022
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2022 NIHR Oxford Biomedical Research Centre